<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04151849</url>
  </required_header>
  <id_info>
    <org_study_id>290/T-20</org_study_id>
    <nct_id>NCT04151849</nct_id>
  </id_info>
  <brief_title>Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota</brief_title>
  <official_title>Complementary Effects of New Diabetes Medications on Adrenal Function and Intestinal Microbiota</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tartu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tartu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this observational study is to describe the effects of glucagon-like
      peptide-1 (GLP-1) receptor agonists and Sodium-Glucose Co-transporter 2 inhibitors ( SGLT-2
      inhibitors) on adrenal function. Secondary endpoint is change in intestinal microbiota.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational study conducted in patients with type 2 diabetes starting treatment
      with either GLP-1 receptor agonist or sodium-glucose cotransporter-2 (SGLT-2) inhibitor.

      Planned study cohort consists of 60 patients: 30 patients starting GLP-1 receptor agonist
      treatment and 30 patients starting SGLT-2 inhibitor treatment. All patients must have
      metformin as background therapy. All other diabetes medications are allowed.

      Patients are tested before starting treatment, at 1 month (stool sample only), 3 months and
      12 months after starting treatment. The primary endpoint is change in overnight urinary
      aldosterone corrected for creatinine.

      Secondary endpoint is change in intestinal microbiota composition.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary aldosterone at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Overnight urinary aldosterone compared to pretreatment level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in gastrointestinal microbiota.</measure>
    <time_frame>At 1 month after starting treatment, at 3 months and 12 months.</time_frame>
    <description>Fecal microbiota will be compared to pre-treatment sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary aldosterone at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Overnight urinary aldosterone at 12 months compared to pretreatment level.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum adrenocorticotropic hormone</measure>
    <time_frame>At 3 months and 12 months.</time_frame>
    <description>Change in adrenocorticotropic hormone in serum compared to pretreatment level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma cortisol</measure>
    <time_frame>At 3 months and 12 months.</time_frame>
    <description>Change in plasma cortisol compared to pretreatment level</description>
  </other_outcome>
  <other_outcome>
    <measure>Urinary cortisol</measure>
    <time_frame>At 3 months and 12 months.</time_frame>
    <description>Change in overnight urinary cortisol compared to pretreatment level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma aldosterone</measure>
    <time_frame>At 3 months and 12 months.</time_frame>
    <description>Change in plasma aldosterone compared to pretreatment level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma renin</measure>
    <time_frame>At 3 months and 12 months.</time_frame>
    <description>Change in plasma renin compared to pretreatment level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum sodium</measure>
    <time_frame>At 3 months and 12 months.</time_frame>
    <description>Change in serum sodium compared to pretreatment level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum potassium</measure>
    <time_frame>At 3 months and 12 months.</time_frame>
    <description>Change in serum potassium compared to pretreatment level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Glycated hemoglobin A1c</measure>
    <time_frame>At 3 months and 12 months.</time_frame>
    <description>Change in glycated hemoglobin A1c compared to pretreatment level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Ceruloplasmin</measure>
    <time_frame>At 3 months and 12 months.</time_frame>
    <description>Change in plasma ceruloplasmin compared to pretreatment level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Ferritin</measure>
    <time_frame>At 3 months and 12 months.</time_frame>
    <description>Change in plasma ferritin compared to pretreatment level.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>GLP-1 receptor agonist treatment</arm_group_label>
    <description>Patients starting treatment with any molecule belonging to the class of GLP-1 receptor agonist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SGLT-2 inhibitor treatment</arm_group_label>
    <description>Patients starting treatment with any molecule belonging to the class of SGLT-2 inhibitors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1 receptor agonist</intervention_name>
    <description>Treatment with GLP-1 agonist for up to 1 year.</description>
    <arm_group_label>GLP-1 receptor agonist treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGLT2 inhibitor</intervention_name>
    <description>Treatment with SGLT2 inhibitor for up to 1 year</description>
    <arm_group_label>SGLT-2 inhibitor treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 2 diabetes who need treatment intensification with SGLT-2 inhibitor or
        GLP-1 receptor agonist.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Type 2 diabetes

          -  HbA1c &lt; 10%

          -  BMI &gt;32

          -  Daily dose of metformin 1,5 g or more.

          -  No change in diabetes treatment at least 90 days before starting the study.

          -  Never used SGLT-2 inhibitors or/and GLP-1 receptor agonist.

          -  Tested negative to glutamic acid decarboxylase 65 autoantibodies.

        Exclusion Criteria:

          -  Pregnancy and lactation.

          -  Use of systemic antibiotic treatment &lt; 60 days before starting the study.

          -  Use of spironolactone &lt; 60 days before starting the study.

          -  Use of oral contraceptives or hormonal replacement therapy.

          -  Use of immunosuppressive drug

          -  Heart failure New York Heart Association III-IV

          -  Severe liver disease.

          -  Malignant disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vallo Volke, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tartu, Institute of Biomedicine and Translational Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vallo Volke, MD, PhD</last_name>
    <phone>+37256489216</phone>
    <email>vallo.volke@ut.ee</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vallo Volke, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Ingrid Reppo</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Estonia</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tartu</investigator_affiliation>
    <investigator_full_name>Vallo Volke</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>GLP-1 receptor agonist</keyword>
  <keyword>SGLT-2 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

